Background
==========

Breast cancer is the leading cause of female cancer death in all industrialised countries (and also worldwide), and the breast is also the leading incident cancer site for females \[[@B1]\]. Therefore, screening methods for breast cancer are of greatest public health importance. Efficiency and efficacy of organised mammography screening programs have been proven in large randomised trials conducted in Europe and North America \[[@B1]-[@B9]\]. For several years already, organised mammography screening programs have been recommended in the EU \[[@B2]\]. Austria is one of the European countries where up to 2006 no organised programs were implemented, but where coverage by spontaneous mammography screening has been reported to be rather high: in a health survey conducted in Austria in 2006-2007 more than 80% of women aged 40+ answered that they had had at least one mammography (ever) and more than 40% had had one in the past year \[[@B10]\]. However, it is known that self-reporting of screening usage overestimates true coverage \[[@B11]\], and our results are in line with this observation comparing the 40% coverage reported in the above-mentioned health survey to 34.5% in our study. In 2006, the Austrian health minister declared mammography to be one of the top health agendas, and in July 2006 a decision was made to implement organised mammography screening programs, namely in a first step in pilot regions, of which Tyrol is the largest.

Two questions now arise. The first question is whether it is really necessary to change the existing spontaneous mammography system, and severe doubts have been raised \[[@B12]\]. Up to now, our knowledge about the performance of the existing spontaneous program is minimal. We have only very limited information from routine reports from the Cancer Registry of Tyrol giving data on stage distribution of breast cancer cases on the population level and on the time trend of breast cancer incidence and mortality \[[@B13]\]. But it is well agreed that this information is by far not sufficient to assess the quality of a mammography program. To date most quality indices recommended by the EU guidelines cannot be calculated because we do not have the necessary information. It is our opinion that it is not justified to offer a mammography screening system to healthy women without having at least profound information on commonly agreed quality measures.

After that, the second question is how to change the existing screening system in the most efficient manner. It is well accepted that there is no uniform solution for implementing an organised screening system in a country, but, instead, when setting up the mammography system the health system conditions in the respective country must be given consideration. The outstanding challenge in introducing a mammography screening program in a country where a spontaneous screening system was conducted for some time is whether to make a smooth transition to an organised system or to completely redesign the existing screening system as was done, for example, in Germany \[[@B14]\]. In Tyrol, a clear decision was made to set up the new program while making best possible use of the existing experience and mammography screening network, which was established over the last fifteen years. Based on the latter strategy, it was possible to establish a country-wide mammography screening program in very short time. The price to be paid was the risk of potential quality problems, because some EU guidelines concerning the structure of the screening system were not fully adhered to.

To our knowledge, also in Europe a number of countries still have no organised mammography programs \[[@B15]\], and therefore the experience in Tyrol can make an important contribution to the question how to switch a health system with spontaneous mammography screening to an organised system that meets well-accepted quality guidelines.

In June 2007, an organised mammography screening program was introduced in two central counties of Tyrol accounting for forty percent of that state\'s population. It was the aim of this study to analyse whether a smooth change from a spontaneous to an organised mammography system can meet the quality indicators recommended by the EU guidelines.

Methods
=======

Study population, invitation
----------------------------

The target population includes all women aged 40 to 69 living in two counties of Tyrol (i.e., the capital of Innsbruck, and the surrounding area) and covered by compulsory social insurance. More than 97% of the population of Tyrol are covered by compulsory social insurance (personal communication). All women in the target population are sent a personal invitation letter: women aged 40-59 annually, and women aged 60-69 biannually. All women are invited regardless of their screening history and their individual cancer status. Invitations are addressed directly to the women; the invitation is to consult a screening unit. Women invited to screening receive detailed information on the screening programme and must sign an informed consent before screening. Mammography screening is offered by 12 screening units, nine of them run by radiologists in private practice and three by hospital outpatient departments at the two public hospitals in the study area. The mammogram is read by only one radiologist; ultrasound (US) is offered to women at the radiologist\'s decision. The mammography result is coded according to the BI-RADS \[[@B16]\] scheme, and the participating women are informed of the screening result immediately after the screening test. Women with BI-RADS 1-2 go back to screening, women with BI-RADS 3 are invited for intermediate screening in six months and women with BI-RADS 4 or 5 are invited for further assessment. Assessment is offered by three hospital radiology units in the study area and includes clinical inspection, mammography, US, MRI and biopsy as needed. The one large assessment unit at Innsbruck University Hospital works closely with a breast cancer centre. As the system is open, women are free to contact the assessment unit irrespective of the mammogram result, and a number of the women go to assessment even if the mammography result is BI-RADS 1,2,3. All program activities were planned carefully and documented in a written protocol. The program is directed by a screening group that meets monthly. A subgroup of the project team is responsible for quality assurance, which is based on quarterly analysis of screening data. According to social insurance regulations, women must first visit their general practitioner who refers them to a screening unit. All radiologists participating in the program had to undergo a training program and need ÖRG (Austrian Radiology Association) certification. In the median, private radiologists performed 2450 mammograms and the three hospital units 1134, 1379 and 4620 mammograms per year. There is no waiting time for mammography. Of the women who were referred to assessment, 64% waited less than five working days, 18% between six and ten working days and 19% more than ten working days.

Data collection
---------------

All mammography units register basic information in a database. It is noteworthy that all mammograms are registered, not only those for women belonging to the target population. Due to data privacy restrictions, women must sign a written consent to permit data transfer to the screening database; if a woman refuses consent, an empty dataset marked simply \"data transfer declined\" is sent to the mammography database. Screening information is transferred to the screening database after pseudonymising the woman\'s social insurance number. The pseudonymisation process permits linkage of data for a specific woman coming from different units and guarantees data confidentiality, because the pseudonymisation process can be reversed only within the screening unit. An analogous procedure was established for assessment units. Finally, data on tumour characteristics are collected by the Cancer Registry of Tyrol. The Cancer Registry has developed a network of various data sources that guarantees a high degree of completeness and validity of cancer data in the population of Tyrol. Details on registry procedures and figures on completeness have been reported elsewhere \[[@B17]\]. The Cancer Registry also collects each patient\'s social insurance number and, consequently, Cancer Registry data can be linked to the screening database by applying the same pseudonymisation process. Cancer Registry data enable us to analyse data on tumour characteristics (e.g., tumour size, lymph node status, information on surgery) and to assess interval cancer cases.

Participation rate should reflect all women undergoing a screening mammography. Part of them refuse consent to permit data transfer. In order to account for these women, we estimated the proportion of all women denying consent and belonging to age group 40-69 as being 56% of 5.8%, namely 3.2%. Thus, the estimated participation rate is equal to the observed participation rate plus 3.2%. Finally, invitation data are provided by the invitation system run by the social insurance carrier. Invitation data are transferred to the screening database as aggregated numbers of invited women per month of invitation, age group (five-year age classes) and county. Recall is defined as call for further assessment or invitation to intermediate screening within six months.

Statistical analysis
--------------------

Plausibility checks are implemented both at the mammography and the assessment unit level and at the central screening database level.

The screening database is realised as STATA datasets. Linkage between screening data, assessment data and Cancer Registry data is based on the pseudonym number. We report numbers and proportions as defined in the EU guidelines. For some indices, population-based rates are computed using the official population data supplied by Statistics Austria. No statistical testing is applied. All reporting is done with STATA Version 9 \[[@B18]\].

Spontaneous mammography screening was introduced in Tyrol already in the early 1990 s. Thus, the underlying background incidence is defined by years 1988-1990, see Table [1](#T1){ref-type="table"}.

###### 

Breast cancer incidence rate in Tyrol before spontaneous screening program 1988-1990 (background incidence) and before changing the screening system 2005-2007

                  40-49^1)^    50-59^1)^    60-69^1)^    Total (40-69)^1)^
  --------------- ------------ ------------ ------------ -------------------
  **1988-1990**                                          
  Breast Cancer   52 (128.8)   54 (176.0)   74 (244.0)   180 (177.5)
  Invasive        50 (123.8)   53 (172.7)   72 (238.5)   175 (172.9)
  In situ         2 (5.0)      1 (3.3)      2 (5.5)      5 (4.6)
  **2005-2007**                                          
  Breast Cancer   82 (146.2)   87 (206.3)   96 (263.0)   265 (196.5)
  Invasive        74 (132.0)   79 (187.3)   89 (245.6)   242 (179.9)
  In situ         8 (14.2)     8 (19.0)     7 (17.4)     23 (16.6)

^1)^Average number of incident cases per year and age-specific rate per 100,000

This study was conducted in conformity to the Helsinki Declaration \[[@B19]\]. The project was approved by the Ethics Committee of Medical University Innsbruck.

Results
=======

From June 2007 to May 2008, 56,432 women in the target population were invited, 40.3% in age group 40-49, 31.1% in age group 50-59 and 28.6% in age group 60-69, see Table [2](#T2){ref-type="table"}. A total of 1,188 invitation letters were returned as undeliverable. Because of their small number, we did not take the returned invitations into consideration for analysis. After deleting N = 80 cases without a BI-RADS classification, we ended up with **17,645 screening cases**in the analysis dataset. Of the screening cases 40.4% were in age group 40-49, 32.2% in age group 50-59 and 27.4% in age group 60-69.

###### 

Invitation system: Number of women invited, number of mammograms performed (numbers and age percentages)

                                                                    40-49   50-59   60-69   Total (40-69)
  ----------------------------------------------------------------- ------- ------- ------- ---------------
  Women invited                                                     22739   17531   16162   56432
  Number of screens in first year                                   7124    5689    4832    17645
  Observed participation rate in first year                         31.3%   32.5%           
  Estimated participation rate in first year^1)^                    34.5%   35.7%           
  Cumulative participation rate after two years^2)^                 54.3%   53.5%   48.2%   52.3%
  Estimated cumulative participation rate after two years^1)\ 2)^   57.5%   56.7%   51.4%   55.5%

^1)^Also a part of women age 40-59 go to mammography screening at a two year interval.

The observed participation rate in the first year of follow-up was 31.3%; after correcting for women declining data transfer to the screening database, the overall participation rate was 34.5% (34.5%, 35.7% and 33.1% in age groups 40-49, 50-59 and 60-69, respectively). After completing a second year of follow-up (end of observation was 31 May 2009), 55.5% of the invited women had undergone at least one screening examination, with a higher participation rate in younger age classes (57.5%, 56.7% and 51.4% for age groups 40-49, 50-59 and 60-69, respectively), see Table [2](#T2){ref-type="table"}.

Screening outcome was negative for 96.6%; 1.6% of cases were recommended for intermediate mammography (six months) after screening (1.2% in age group 60-69), 1.8% were referred for further assessment (1.4% in age group 60-69) and in 10 cases the screening outcome was unknown (Table [3](#T3){ref-type="table"}).

###### 

Screening outcome

                                                    40-49          50-59          60-69          Total
  ------------------------------------------------- -------------- -------------- -------------- ---------------
  Negative                                          6853 (96.2%)   5482 (96.4%)   4704 (97.4%)   17039 (96.6%)
  Intermediate screening test following screening   125 (1.8%)     95 (1.7%)      57 (1.2%)      277 (1.6%)
  Assessment                                                                                     
   Recommended                                      142 (2.0%)     109 (1.9%)     68 (1.4%)      319 (1.8%)
   Performed                                        140 (2.0%)     109 (1.9%)     66 (1.4%)      315 (1.8%)
  Unknown^1)^                                       4              3              3              10
  **Total**                                         **7124**       **5689**       **4832**       **17645**

^1)^BI-RADS 0 without assessment was treated as unknown

According to screening policy, the screening radiologists were free to perform additional US. The reason for additional US was recorded as breast density grades according to the American College of Radiology (ACR) 3 or 4 in 37.6%, equivocal findings on mammography in 16.9%, and other nonspecified reasons in 45.5% of cases. Overall, 83.3% of women had an additional US examination, with clear differences between the age groups: the proportions were 89.2%, 81.3% and 77.1% in age groups 40-49, 50-59 and 60-69, respectively (Table [4](#T4){ref-type="table"}).

###### 

Additional ultrasound imaging at screening

                                              40-49          50-59          60-69          Total
  ------------------------------------------- -------------- -------------- -------------- ---------------
  Ultrasound added to mammography screening   6358 (89.2%)   4624 (81.3%)   3723 (77.1%)   14705 (83.3%)
  Reason for ultrasound:                                                                   
   Breast density (ACR 3/4)                   2855 (44.9%)   1638 (35.4%)   1041 (28.0%)   5534 (37.6%)
   Equivocal finding                          1037 (16.3%)   810 (17.5%)    635 (17.1%)    2482 (16.9%)
   Other                                      2466 (38.8%)   2176 (47.1%)   2047 (55.0%)   6689 (45.5%)

Of 315 assessments performed, 38.4% had a core biopsy (45.5% in age group 60-69), 7.6% a fine needle biopsy and 1.9% (six cases) an open biopsy. This means that of 1000 women screened, nine had a biopsy (8 in age group 60-69) and 0.3 underwent an open biopsy (Table [5](#T5){ref-type="table"}). Of all assessments 75.6% were negative, 2.9% were recommended for intermediate screening and in 68 (21.6%) screening cases breast cancer was diagnosed (12.9%, 20.2% and 42.4% in age groups 40-49, 50-59 and 60-69 respectively), see Table [6](#T6){ref-type="table"}.

###### 

Assessment procedure

                                    40-49        50-59         60-69        Total
  --------------------------------- ------------ ------------- ------------ -------------
  **Additional imaging**                                                    
   Ultrasound                       140 (100%)   106 (97.2%)   61 (92.4%)   307 (97.5%)
   MRI                              24 (17.1%)   21 (19.3%)    21 (31.8%)   66 (21.0%)
  **Biopsy**                        63 (45.0%)   51 (46.8%)    37 (56.1%)   151 (47.9%)
   Core biopsy                      51 (36.4%)   40 (36.7%)    30 (45.5%)   121 (38.4%)
   Fine needle biopsy               10 (7.1%)    10 (9.2%)     4 (6.1%)     24 (7.6%)
   Open biopsy                      2 (1.4%)     1 (0.9%)      3 (4.5%)     6 (1.9%)
  Biopsy rate per 1000 mammograms   8.8          9.0           7.7          8.6
  PPV for core biopsy^1)^           35.3.4%      47.5%         80.0%        50.4%
  PPV for open biopsy^2)^                                                   66.7%
  **Total**                         **140**      **109**       **66**       **315**

^1)^For all fine needle biopsies the result was benign.

^2)^For six open biopsies two were benign and four malignant. Because of small numbers, PPV is shown only for the total.

###### 

Assessment outcome

                                                                                   40-49         50-59        60-69        Total
  -------------------------------------------------------------------------------- ------------- ------------ ------------ -------------
  Negative                                                                         117 (83.6%)   85 (78.0%)   36 (54.5%)   238 (75.6%)
  Recommendation for intermediate screening after assessment                       5 (3.6%)      2 (1.8%)     2 (3.0%)     9 (2.9%)
  Breast cancer                                                                    18 (12.9%)    22 (20.2%)   28 (42.4%)   68 (21.6%)
   In situ                                                                         4 (2.9%)      2 (1.8%)     1 (1.5%)     7 (2.2%)
   Invasive                                                                        14 (10.0%)    20 (18.3%)   27 (40.9%)   61 (19.4%)
  Breast cancer detection rate per 1000 mammograms                                 2.5           3.9          5.8          3.9
  Ratio screening breast cancer detection rate vs. background incidence rate^1)^   1.9           2.2          2.4          2.2
  **Total**                                                                        **140**       **109**      **66**       **315**

^1)^Background incidence rate: see Table 1

For all fine needle biopsies, the diagnosis was benign. The positive predictive value of core biopsy was 50.4% in total and 35.3%, 47.5% and 80.0% in age groups 40-49, 50-59 and 60-69, respectively. The six open biopsies showed two benign and four malignant cancer cases.

Of the 68 breast cancer cases, 61 were invasive, and seven were ductal carcinoma in situ. The cancer detection rate was 3.9 per 1000 mammograms in total and 2.5, 3.9 and 5.8 in age groups 40-49, 50-59 and 60-69 respectively, see Table [6](#T6){ref-type="table"}.

Of all invasive cancers detected, 34.4% were less then 10 mm in size and 65.6% were node-negative, without differences for age group, see Table [7](#T7){ref-type="table"}.

###### 

Characteristics of invasive cancers

                                 40-49        50-59        60-69        Total
  ------------------------------ ------------ ------------ ------------ ------------
  Tumour size (mm):              13.5; 3-50   14; 2-60     12; 1-49     13; 1-60
   Median; range                                                        
  Tumour size (mm):                                                     
   \<= 10 mm                     6 (42.9%)    6 (30.0%)    10 (37.0%)   21 (34.4%)
   11-20 mm^1)^                  6 (42.9%)    8 (40.0%)    12 (44.4%)   26 (42.6%)
   \>20 mm                       3 (21.4%)    6 (30.0%)    5 (18.5%)    14 (23.0%)
  Lymph node involvement         5 (35.7%)    7 (35.0%)    9 (33.3%)    21 (34.4%)
  Total                          14           20           27           61
  Tumor stage according to TNM                                          
  pT1                            12 (85.7%)   14 (70.0%)   22 (81.5%)   48 (78.7%)
  pT2                            2 (14.3%)    5 (25.0%)    5 (18.5%)    12 (19.7%)
  pT3                                         1 (5.0%)                  1 (1.6%)
  pN0                            9 (64.3%)    13 (65.0%)   18 (66.7%)   40 (65.6%)
  pN1                            4 (28.6%)    4 (20.0%)    6 (22.2%)    14 (23.0%)
  pN2                            1 (7.1%)     2 (10.0%)    2 (7.4%)     5 (8.2%)
  pN3                                         1 (5.0%)     1 (3.7%)     2 (3.3%)
  M0                             13 (92.9%)   19 (95.0%)   26 (96.3%)   58 (95.1%)
  M1                             1 (7.1%)     1 (5.0%)     1 (3.7%)     3 (4.9%)

After linking screening data and Cancer Registry data (only depseudonymised data), we observed a total of six interval cancer cases within one year after screening, four in age group 40-49, one in age group 50-59 and one in age group 60-69. The interval cancer rate was 34 per 100,000 mammograms; this is 19% of the underlying background incidence rate (defined by years of diagnosis 1988-1990). Details are shown in Table [8](#T8){ref-type="table"}, which shows the most important quality indicators defined in the EU guidelines restricted to age group 50-69, because EU recommendations are given for that age group.

###### 

EU Guidelines, quality indicators (with accepted and desired levels)

  --------------------------------------------------------------------------------------------------------------------------------------
                                                                     Tyrol 50-69                              EU-accepted   EU-desired
  ------------------------------------------------------------------ ---------------------------------------- ------------- ------------
  Attendance proportion                                              54.2                                     \>70          \>75

  Recall rate^1)^                                                    3.1 (327/10521)                          \<7%/\        \<5%/\
                                                                                                              \<5%          \<3%

  Interval cancer rate/Background incidence rate (BIR) 0-11 months   9% (two interval cancers in age 50-69)   30%           \<30%

  Breast cancer detection rate                                       2.3 \* BIR                               3\*BIR        \>3\*BIR

  Stage II+/Total cancers screen-detected                            38.0% (19/50)                            NA            \<30%

  Invasive cancers ≤ 10 mm/Total invasive cancers                    34.0% (16/47)                            NA            \>= 25%

  Proportion of invasive cancers that are \< 15 mm in size           51.1% (24/47)                            50%           \>50%

  Invasive cancer/Total cancers screen-detected                      94% (47/50)                              90%           80%-90%

  Node-negative cancer/Total invasive cancers screen-detected        66.0% (31/47)                            NA            \>70%

  Benign to malignant open surgical biopsy ratio                     0:1 (0:4)                                \<=1:2        \<=1:4

  Benign to malignant core biopsy ratio                              1:0.9 (60:64)                                          
  --------------------------------------------------------------------------------------------------------------------------------------

^1)^Recall is defined as call for further assessment or invitation to intermediate screening within six months

Discussion
==========

We analysed the situation after a first year of introducing organised mammography screening in two counties in Tyrol accounting for 40% of that state\'s population. The organised program was established in a smooth transition from the existing spontaneous mammography screening system, namely by introducing a written protocol, a personal invitation system, a training program, and by setting up a screening database allowing us to investigate performance and outcome parameters in detail. Although not all EU recommendations have been followed to date, most quality indicators are in the range of accepted and/or desired levels given by the EU guidelines: the proportion of cases called for further assessment (20 per 1000 mammograms), the biopsy rate (9 per 1000 mammograms), the proportion of invasive screening-detected cancer (89.7%), the proportion of invasive cancer ≤ 10 mm in size (34.4%) and the interval cancer rate expressed as a multiple of the background incidence rate (19%). The average number of screens read by a radiologist (about 2400) does not meet the EU recommendation of 5000. However, in about four of five women an additional US is done, which is known to improve the sensitivity of the screening test, see for example \[[@B20],[@B21]\].

Some of the parameters are near the value expected in subsequent screening rounds and not in a first round (for example, recall rate and breast cancer detection rate). However, we must remember that the organised program was introduced after fifteen years of the spontaneous screening program. Some indicators like proportion of stage II+ cancers and node-negative cancer are slightly outside the EU-accepted levels. Some of the observations could be due to small numbers (we observed a total of 68 cancer cases). So it is too early to come to final conclusions on the mammography screening model we describe here.

Only one indicator clearly misses the EU recommendations, namely the participation rate. However, participation rate depends not only on program organisation, but also on cultural background. A look at neighbouring German-speaking countries, which should have a similar culture, shows participation rates of 54% in Germany \[[@B14]\] and 25.9% to 65.9% in five cantons of Switzerland \[[@B22]\]. Thus, a cumulative participation rate of 55% in the first two years would seem to be rather successful by comparison to that of countries with a similar cultural background, albeit not the goal we aimed for.

Among the strengths of the Tyrolean breast cancer screening program is its implementation: within a short time and with minimal additional resources it was possible to set up an organised population-based screening program that - at least at evaluation after one year - met all of the EU quality indicators except participation rate. It was not necessary to set up extra screening units; instead, the program used the existing network of screening and assessment units. In terms of epidemiology, another of the program\'s strengths is a complete pseudonymised database that covers all mammography exams and can be linked to the Cancer Registry data. The database was set up in a very short time, it is up to date within one month and serves as a very important tool for monitoring the program quality indicators or, more generally speaking, for all kinds of quality assurance tasks.

Nevertheless, the program differs from many organised programs in the EU in three aspects. Firstly, we also included women aged 40-49. During previous spontaneous screening campaigns women aged 40-49 were officially invited to participate in mammography screening. The discussion in the USA after publishing the revised recommendation by USPSTF \[[@B23],[@B24]\] shows that it is very challenging and difficult for women to understand why a service is cancelled that was recommended for several years. Without well founded data, we feel it is not justified to discontinue screening in age class 40-49. We are collecting detailed data and will evaluate the goods and harms \[[@B23],[@B25]\] in coming years. In addition, the analysis of breast cancer mortality in Tyrol in the past decade shows that mortality decrease was greatest in women aged 40-49, an effect that can at least partly be attributed to spontaneous screening \[[@B13]\].

Secondly, we offer breast US as an additional diagnostic tool in screening. In opportunistic screening in Tyrol, US was offered to women with dense breasts (ACR density grades 3 and 4) and with inconclusive findings on mammography \[[@B26],[@B27]\]. The line of reasoning concerning screening in age group 40-49 also holds for adjunct US, bearing in mind that adjunct US was offered during the last decade. It has been shown by various authors that the additional use of US can improve cancer detection rates, especially in younger women and women with dense breasts \[[@B20],[@B21],[@B26]\]. The relative percentage of carcinomas found in supplemental breast US examinations as a fraction of the total number of detected cancers was reported by four studies with a mean percentage of 22.5% (15%-34%) \[[@B19]\]. In the second year of the organised program we collected detailed data allowing us to analyse the contribution of US to sensitivity and specificity outside the framework of studies, namely in a population-based setting.

And thirdly, we were not able to implement double reading during the piloting phase. Interestingly, performance parameters, especially interval cancer rate, showed that also without double reading an acceptable quality level was achieved. The question of the completeness of interval cancer rate depends on the completeness of the Cancer Registry of Tyrol, which covers the target population. We analysed quality measures for the Cancer Registry in detail, also completeness, and found a high degree of completeness, both for all cancer sites and for breast cancer \[[@B17]\]. Therefore, we think it is unlikely that we missed interval cancers. However, the numbers are small and we cannot exclude the possibility that we missed one or two cases, which would mean a 33% increase in the interval cancer rate (from 6 to 8 cases). Clearly, a longer observation period is necessary before coming to a final conclusion on this parameter. This observation could in part be explained by short screening intervals in the age group 40-59 and by the use of additional US. Nevertheless, double reading will be introduced in the regular screening program after concluding the piloting phase.

Also, as we do not have a scheduling system, women are invited to consult the screening unit at any time that is convenient to them. The time when the invitation is sent is independent of a woman\'s individual screening history. The latter point is corrected in the next invitation round, which required a change in the written consent for reasons of data privacy.

Many countries have had a mammography screening program running for decades or for a shorter time. On the other hand, six EU member states still have no organised nationwide breast cancer screening program, and in seven member states a nationwide rollout was in 2007 \[[@B15]\]. What can be learned from our experience by countries that are thinking of introducing or are already in the process of planning to introduce a mammography screening program? In our opinion, the greatest difference between our approach and many other approaches is the smooth transition made from the existing spontaneous program to organized population-based screening. We made use of the network of screening and assessment units that had already been set up during spontaneous screening. What we added was an invitation system covering the entire population of Tyrol, a screening database that allows quality indices to be monitored and a well-defined training program for both screening and assessment units. With this strategy we were able to meet most EU quality indices in a very short time.

Conclusions
===========

A smooth transition from a spontaneous to an organised mammography screening system that uses the existing screening units, introduces an invitation system and a quality assurance program (including a screening database) can meet the quality indicators recommended by European guidelines in a short time and with minimal additional resources. However, it will be necessary to introduce double reading, to change the rule for BI-RADS 3 and to concentrate on actions toward improving the participation rate.
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